Saturday, July 11, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Autoimmune & immunology R&D Pipeline

Autoimmune, rheumatology, and immunology biologics in clinical development.

Programs 985

Quick answer

Autoimmune & immunology: NovaPharmaNews indexes 985 autoimmune & immunology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Autoimmune, rheumatology, and immunology biologics in clinical development.

Top sponsors

Pipeline programs

Page 10 of 21

  1. CA061-1011

    Celgene Europe Limited

    Lupus Nephritis, Systemic Lupus Erythematosus

    phase 2 small molecule active

    1 trial

  2. CB-01-35/01

    Cosmo Technologies Ltd

    patients with mild to moderate left-sided ulcerative colitis

    phase 2 small molecule active

    1 trial

  3. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial

  4. CDFV890B12201

    Novartis Pharmaceuticals

    Knee Osteoarthritis

    phase 2 small molecule active

    1 trial

  5. CEP-701 20mg

    Teva Pharma GmbH

    Psoriasis

    phase 2 small molecule completed

    1 trial

  6. CF101

    Can-Fite BioPharma

    Rheumatoid Arthritis

    phase 2 small molecule completed

    3 trials

  7. CF101

    Can-Fite BioPharma

    Osteoarthritis of the Knee

    phase 2 small molecule terminated

    1 trial

  8. CF101 1mg

    Can-Fite BioPharma

    Plaque Psoriasis

    phase 2 small molecule completed

    1 trial

  9. CLNP023K12201

    Novartis Pharmaceuticals

    Lupus Nephritis Class III-IV, +/- V

    phase 2 small molecule active

    1 trial

  10. CM336 Injection

    The First People's Hospital of Lianyungang

    Autoimmune Bullous Disease

    phase 2 mab active

    1 trial

  11. CMAS825D12201

    Novartis Pharmaceuticals

    Autoinflammatory diseases including NLRC4-Gain of Function (GOF) also known as AIFEC (autoinflammation with infantile enterocolitis), X-linked Inhibitor of Apoptosis Protein (XIAP) deficiency, or Cell division control protein 42 homolog (CDC42) mutation.

    phase 2 small molecule active

    1 trial

  12. CQUC398A12201

    Novartis Pharmaceuticals

    Knee osteoarthritis

    phase 2 small molecule active

    1 trial

  13. CS008

    Lacuna Pharma Pty Ltd

    Rheumatoid Arthritis

    phase 2 small molecule active

    1 trial

  14. CTX112

    S.A.

    Warm Autoimmune Hemolytic Anemia (WAIHA)

    phase 2 mab active

    1 trial

  15. CVAY736A2202

    Novartis Pharmaceuticals

    Rheumatoid Arthritis, Sjögren’s Disease, Systemic Lupus erythematosus

    phase 2 small molecule active

    1 trial

  16. CVAY736Q12202B

    Novartis Pharmaceuticals

    Immune thrombocytopenia (ITP) Warm autoimmune hemolytic anemia (wAIHA)

    phase 2 small molecule active

    1 trial

  17. CYTB323G12101

    Novartis Pharmaceuticals

    Systemic Lupus Erythematosus., Lupus Nephritis

    phase 2 small molecule active

    1 trial

  18. CYTB323J12201

    Novartis Pharmaceuticals

    Active, refractory systemic lupus erythematosus (SLE), and active, refractory lupus nephritis (LN)

    phase 2 small molecule active

    1 trial

  19. CYTB323M12101B

    Novartis Pharmaceuticals

    Difficult to treat rheumatoid arthritis, Severe, refractory Sjogren’s disease with organ involvement

    phase 2 small molecule active

    1 trial

  20. CYTB323O12101

    Novartis Pharmaceuticals

    Treatment-resistant generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  21. Ciprofloxacin

    United Therapeutics Europe Ltd

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  22. Cizutamig

    Lacuna Pharma Pty Ltd

    Severe, treatment refractory primary Sjögren’s disease (pSjD), Severe, treatment refractory idiopathic inflammatory myopathy (IIM), Severe, treatment refractory systemic sclerosis (SSc), Severe, treatment-refractory, seropositive (anti-citrullinated protein antibody (ACPA) and/or rheumatoid factor positive) rheumatoid arthritis (RA)

    phase 2 small molecule active

    1 trial

  23. D9690C00006

    AstraZeneca AB

    Crohn’s Disease and an Ileostomy

    phase 2 small molecule active

    1 trial

  24. DNTH103

    Dianthus Therapeutics, Inc. /DE/

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  25. DNTH103-MG-201

    Dianthus Therapeutics, Inc. /DE/

    Generalized Myasthenia Gravis

    phase 2 small molecule active

    1 trial

  26. DRI17821

    Sanofi-aventis Healthcare Pty Ltd

    Rheumatoid arthritis

    phase 2 small molecule active

    1 trial

  27. DRI17849

    Sanofi-aventis Healthcare Pty Ltd

    Psoriasis

    phase 2 small molecule active

    1 trial

  28. DRI18450

    Sanofi-aventis Healthcare Pty Ltd

    Crohn’s disease

    phase 2 small molecule active

    1 trial

  29. Dapagliflozin 10mg Tab

    The University of Hong Kong

    Lupus Nephritis

    phase 2 small molecule active

    1 trial

  30. Daxdilimab

    Amgen

    Lupus Nephritis

    phase 2 small molecule terminated

    1 trial

  31. Delayed Release 6 mercaptopurine

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule terminated

    1 trial

  32. Delayed Release 6MP or Calcitriol vs. Purinethol

    Teva Pharma GmbH

    Crohn's Disease

    phase 2 small molecule completed

    1 trial

  33. Descartes-08

    Cartesian Therapeutics

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule active

    1 trial

  34. Descartes-08

    Cartesian Therapeutics

    Myasthenia Gravis, Generalized

    phase 2 small molecule active

    1 trial

  35. Descartes-08

    Cartesian Therapeutics

    Childhood-onset Systemic Lupus Erythematous

    phase 2 small molecule active

    1 trial

  36. Dex 21-P

    Quince Therapeutics

    Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  37. Diamyd

    Wuhan Createrna Science and Technology Co., Ltd

    Latent Autoimmune Diabetes in Adults (LADA)

    phase 2 small molecule active

    1 trial

  38. Double-Blind 0.2mg CBP-307

    S.L

    Moderate to Severe Ulcerative Colitis

    phase 2 small molecule completed

    1 trial

  39. Duobrii

    Bausch & Lomb Incorporated

    Plaque Psoriasis

    phase 2 small molecule active

    1 trial

  40. Dupilumab

    Regeneron UK Limited

    Colitis Ulcerative

    phase 2 small molecule active

    1 trial

  41. EP-104IAR 25 mg

    EUPRAXIA PHARMACEUTICALS INC.

    Osteoarthritis, Knee

    phase 2 small molecule completed

    1 trial

  42. Efavaleukin alfa

    Amgen

    Ulcerative Colitis

    phase 2 small molecule terminated

    1 trial

  43. Elsubrutinib

    AbbVie

    Systemic Lupus Erythematosus (SLE)

    phase 2 small molecule completed

    1 trial

  44. Eltrekibart

    Eli Lilly and Company

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  45. Enekinragene Inzadenovec (PCRX-201)

    Pacira Ireland Limited

    Osteoarthritis (OA) of the Knee

    phase 2 mab active

    1 trial

  46. Enpatoran Placebo, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  47. Enpatoran low dose

    Serono Europe Limited

    Systemic Lupus Erythematosus

    phase 2 small molecule completed

    1 trial

  48. Entyvio 300 mg powder for concentrate for solution for infusion

    Takeda

    Ulcerative Colitis or Crohn's Disease

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many autoimmune & immunology pipeline programs are tracked?

985 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.